Managing Hypertension in MI Patients: Key Updates for Clinicians & Place of Telmisartan and Metoprolol

Hypertension remains a major determinant of adverse outcomes after myocardial infarction (MI), contributing to recurrent ischemia, adverse left ventricular remodeling, heart failure, and cardiovascular mortality. The 24-hour ambulatory blood pressure monitoring (ABPM) data suggests that ~40% of early post-MI patients have mean daily BP above the recommended <130/80 mmHg target, highlighting the need to move beyond office BP reduction toward sustained 24-hour BP control, neuro-hormonal modulation, and comprehensive cardiovascular risk reduction with evidence-based RAAS inhibition and β-blockade.¹

Hypertension & MI: Why Does It Need a Different Therapeutic Approach?

Following myocardial infarction, persistent activation of the sympathetic nervous system (SNS) and the renin–angiotensin–aldosterone system (RAAS) extends beyond an initial compensatory response to become a major driver of adverse ventricular remodeling. The resulting vasoconstriction, endothelial dysfunction, oxidative stress, inflammation, myocardial fibrosis, and increased myocardial oxygen demand accelerate the risk of progression to heart failure and recurrent ischemic events. Consequently, hypertension management in MI should target both blood pressure and heart rate, while attenuating neuro-hormonal activation to mitigate the progression of unfavorable CV outcomes.^{2, 3}

Hypertension Management in Myocardial Infarction: Evidence with Telmisartan & Metoprolol

Effect of Metoprolol Succinate After MI: The BETAMI–DANBLOCK trial published in 2025 re-examined the role of long-term β-blockade in the contemporary reperfusion era among 5,574 patients with recent myocardial infarction and LVEF ≥40%. In this multi-centre, randomized, open-label trial with blinded endpoint assessment, patients were assigned within 14 days of MI to β-blocker therapy (n=2,783) or no β-blocker (n=2,791), with metoprolol succinate being the predominant β-blocker utilized. Over a median follow-up of 3.5 years, β-blocker therapy was associated with a 15% relative risk reduction in the composite of all-cause mortality or major adverse cardiovascular events (14.2% vs 16.3%; HR 0.85) and a 27% relative risk reduction in recurrent MI (5.0% vs 6.7%; HR 0.73), reaffirming the role of β1-selective blockade in appropriately selected post-MI patients.⁴

Effect of Telmisartan in High CV Risk Patients: The landmark ONTARGET trial evaluated 25,620 high-risk patients aged ≥55 years with established cardiovascular disease or diabetes with end-organ damage. Patients were randomized to telmisartan 80 mg, ramipril 10 mg, or combination therapy and followed for a median of 56 months. Telmisartan was non-inferior to ramipril for the composite of cardiovascular death, myocardial infarction, stroke, or heart failure hospitalization (16.7% vs 16.5%; RR 1.01; 95% CI 0.94–1.09), while demonstrating better tolerability with fewer cough and angioedema events. These findings established telmisartan as an evidence-based ARB offering cardiovascular protection comparable to ramipril, with superior tolerability in high-risk patients.⁵

Effect of Telmisartan–Metoprolol FDC on 24-Hour Blood Pressure Control - Indian Experience: A prospective, open-label, multi-centre study across seven Indian centres evaluated metoprolol ER–telmisartan FDC in 88 patients with uncontrolled hypertension and stable ischemic heart disease using serial 24-hour ABPM. At 8 weeks, mean 24-hour SBP and DBP decreased by 14.41 mmHg and 9.52 mmHg, respectively (p<0.0001). Significant improvements were also observed in Treatment on Variability Index (TOVI) and Smoothness Index, indicating consistent and homogeneous BP reduction throughout the dosing interval. All adverse events were mild and unrelated to treatment, supporting favourable tolerability. These findings support the clinical value of sustained 24-hour BP control in hypertensive patients with ischemic heart disease.⁶

Guideline and Real-World Perspective on the Telmisartan–Metoprolol Combination

Contemporary guidelines support RAAS inhibition and β-blockade in patients with compelling cardiovascular indications such as prior MI, coronary artery disease, LV dysfunction, heart failure, or need for heart-rate control.

Guideline	Key Considerations	Clinical Relevance to Telmisartan–Metoprolol
Indian Society of Hypertension (InSH) Consensus Guideline, 2025 7	Recommends individualized antihypertensive therapy with early use of single-pill combinations where appropriate. β-blockers remain important in patients with compelling cardiovascular indications, while RAAS inhibitors continue as a cornerstone of antihypertensive therapy.	Supports a phenotype-based approach in hypertensive patients with CAD, prior MI, or elevated sympathetic drive.
2025 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults 8	In adults with hypertension and compelling cardiovascular indications such as recent MI or angina, β-blockers, ARBs, or ACE inhibitors are recommended as first-line therapy, with additional antihypertensive agents added as required to achieve BP targets.	Supports complementary RAAS inhibition and β-blockade in hypertensive patients following MI, facilitating both optimal BP control and secondary cardiovascular prevention.
ESC Guidelines for the Management of Elevated Blood Pressure and Hypertension, 2024 9	β-blockers are recommended when hypertension coexists with CAD, prior MI, HF, AF, or when heart-rate control is required. RAAS inhibitors remain among the preferred first-line antihypertensive drug classes.	Reinforces integrated BP reduction, HR control, and cardiovascular protection in hypertension with MI.

The telmisartan–metoprolol combination seems an appropriate consideration in hypertensive patients after MI where BP control must be integrated with heart rate reduction, ischemic protection, and neuro-hormonal modulation to optimize CV outcomes.

These guideline-based considerations are reflected in Indian practice too. The most recent 2026 published ROBUST clinical survey (JAPI, 2026), involving 1000 HCPs, reported routine β-blocker use by 75% of clinicians, with metoprolol emerging as a preferred β-blocker in CAD and hypertension with coexisting ischemic heart disease (IHD).¹⁰

Final Message

• In hypertension with MI, BP control should be viewed as part of secondary cardiovascular prevention, with additional emphasis on 24-hour BP stability, heart rate control, and neuro-hormonal modulation.
• Current evidence and guidelines support individualized RAAS inhibitor–β-blocker use in selected post-MI patients, particularly those with CAD, LV dysfunction, elevated heart rate, or concomitant AF.
• Telmisartan and metoprolol offer complementary clinical effects; telmisartan supports RAAS-mediated cardiovascular protection, while metoprolol addresses sympathetic drive, heart rate, and ischemic burden. Importantly, both agents have established evidence of CV outcomes.

Abbreviations:

MI: Myocardial Infarction; BP: Blood Pressure; ABPM: Ambulatory Blood Pressure Monitoring; SNS: Sympathetic Nervous System; RAAS: Renin–Angiotensin–Aldosterone System; CV: Cardiovascular; LVEF: Left Ventricular Ejection Fraction; HR: Hazard Ratio; RR: Risk Ratio; ARB: Angiotensin II Receptor Blocker; FDC: Fixed-Dose Combination; ER: Extended Release; SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure; TOVI: Treatment on Variability Index; AF: Atrial Fibrillation; PCI: Percutaneous Coronary Intervention; BARC: Bleeding Academic Research Consortium; CAD: Coronary Artery Disease; LV: Left Ventricular; IHD: Ischemic Heart Disease; InSH: Indian Society of Hypertension; ESC: European Society of Cardiology.